Click on the link below for a webcast presentation of Waldenstrom's Macroglobulinemia Biology and Treatment Options by Eva Kimby, M.D., Ph.D., Karolinska Institute, Stockholm, Sweden.
Webcast - WM Biology and Treatment Options Presented by Dr. Eva Kimby, Karolinska Institute
This presentation was caputured during a live conference held on October 24, 2009 in New York City at the 14th Annual North American Forum on Lymphoma.
This project was supported through cooperative agreement number 1U58DP1110 from the Centers for Disease Control Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.
Treatment guidelines published by Mayo Clinic WM researchers in September, 2010. In the article below, Mayo Clinic researchers provide their recommendations on timing and choice of therapy.
Ansell, Stephen M., et al. "Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratificaton of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines." Mayo Clinic Proceedings. Volume 85, Issue 9 (September, 2010): pp. 824-833. Also available online. (Article provided with permission of authors.)
NOTE: The mSMART guidelines undergo period review and adjustment as reserchers gain more knowledge about WM. Please view their mSMART website for updated versions of their recommendations.
Treatment recommendations, published by Dr. Steve Treon of the Dana Farber Cancer Institute in September 2009 in the Blood Journal. In the article below, Dr. Treon presents his guidelines into how and when WM should be treated.
Treon, Stephen P. "How I Treat Waldenstrom's Macroglobulinemia." Blood. Vol. 114, Issue 12 (17 Sep 2009); pp. 2375-2385. Also available online. (Article provided with permission of the author.)
A downloadable (but not printable) review of the most recent results (as of September, 2010) reported for the use of new combinations and new drugs in patients witn WM at different stages of the disease.
Garcia-Sanz, Ramón and Ocio, Enrique M. "Novel treatment regimens for Waldenstrom's macroglobulinemia." Expert Rev. Hematol. 3(3), 339-350 (2010). (Article provided with permission of Expert Reviews.)
A review of 44 published clinical trials in WM, along with recommendations for new response criteria and definitions of time to event analysis to be used in reporting data from future clinical trials (April, 2010).
Rourke, Meghan, Anderson, Kenneth C., and Ghobrial, Irene M. "Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients". Leukemia & Lymphoma 2010; 51(10): 1779-92. (Article provided with permission of Irene M. Ghobrial).
A variety of articles on the biology and potential side effects of rituximab (Rituxan) that were published in the journal Seminars in Hematology, Volume 47, Issue 2, April 2010. (Articles provided with permission of Elsevier/Rightslink Copyright Clearance Center.)
The website chemocare.com is sponsored by the Scott Hamilton CARE Initiative at the Cleveland Clinic Taussig Cancer Center. It lists the most commonly used chemotherapy drugs, along with information about how these drugs are administered and their potential side effects.